Skip to content
Dose Brief
Menu
No. 8 on the board · Grade BEditorial review

Hims & Hers review

Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.

Visit Hims & Hers Editorial review — no commercial relationship.
Semaglutide
$199/mo
Tirzepatide
Not disclosed
Coverage
All 50 states
Brand-name
Compounded only
On the trackerRisingprice risingApp-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.

The scorecard

Hims & Hers scored on our six Brief Score factors. See the methodology.

Price Stability83/100
Supply Reliability86/100
Transparency83/100
Access Breadth88/100
Clinical Oversight86/100
Track Record86/100

What we like

  • Nationwide
  • Slick app experience
  • Strong brand trust

The caveats

  • Tirzepatide pricing not consistently disclosed
  • Compounded supply has drawn regulatory scrutiny industry-wide

The brief

Best for: Readers who want a familiar, app-driven consumer brand and nationwide access. Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.

Ranked #8 of 9 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 8 other providers we've reviewed, in our overall ranking order.

Pricing, states and verification reflect Hims & Hers's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Hims & Hers's site. Not medical advice; see our disclosure.

← Back to all rankings